Chinere biological (300122.SZ): Composition of DTaP-Hib quadrivalent vaccine approved for clinical trials.

Wisdom Finance App news, BeiGene (300122.SZ) announced that the company recently learned that the adsorbed cell-free diphtheria (component) b-type influenza streptococcus (conjugate) combination vaccine developed by its wholly-owned subsidiary Beijing Beigene Lush bamboo biopharmaceutical Co., Ltd. (referred to as "Beigene Lush bamboo") has received the Drug Clinical Trial Approval Notification from the National Medical Products Administration, allowing the clinical trial of the preventive day effect caused by pertussis, diphtheria, tetanus and infection caused by b-type influenza streptococcus. The company will conduct related clinical trials as soon as possible according to the requirements of the Drug Clinical Trial Approval Notification.